VANGUARD RESEARCH GROUP
NEWSLETTER

August 2022

JULY/AUGUST WEBINAR

Mark your calendar for our **August 31st webinar on the Concept of Clinical High-Risk for Psychosis.**

If you missed our past webinars, you can find them here:

http://vanguardresearchgroup.com/past-vrg-webinars/

THE ROLE OF TECHNOLOGY IN BEHAVIORAL HEALTH

Over the last decades, technology has become an integral part of behavioral health care and the COVID-19 pandemic accelerated the development with its shift to telemedicine. Whether in the area of data collection, accessing care, employing innovating treatment options – there is a multitude of possibilities and also challenges. Review below article for an overview:

https://www.nimh.nih.gov/health/topics/technology-and-the-future-of-mental-health-treatment#:~:text=Introduction,increase%20understanding%20of%20mental%20wellbeing.

VRG has been involved in the development and execution of a number of behavioral health studies involving a range of technology and behavioral health apps. The "Improving Care, Reducing Cost" (ICRC) study for example provided a treatment program for recently discharged schizophrenia patients and included an app on cognitive behavioral treatment for paranoia and voices, a digital family support program and technology-based decision assistant for psychiatrists to support pharmacological treatment. Find a recent publication on the program attached to this newsletter and an invitation to participate in our upcoming technology-based studies below!

VRG INVITES YOU TO JOIN OUR NEW FUTURE STUDIES AND PROJECTS

- **A NOVEL PHARMACOLOGICAL TREATMENT FOR ACUTE AGITATION IN SCHIZOPHRENIA / BIPOLAR DISORDER FOR USE IN CRISIS STABILIZATION UNITS / PSYCH ER.**
- **A NOVEL PHARMACOLOGICAL TREATMENT FOR ACUTE SUICIDAL IDEATION IN BIPOLAR DISORDER FOR USE IN CRISIS STABILIZATION UNITS / PSYCH ER.**
- **TESTING A NEW THERAPY APP PROVIDING TREATMENT FOR MDD**
- **SMARTPHONE-BASED MEASURING OF BIOMARKERS SUCH AS HEART AND RESPIRATION RATE**
- ***DON'T FORGET: WE ALSO INVITE YOU TO CONTACT US WITH YOUR QUALITY IMPROVEMENT PROJECTS FOR CONSUTLATION AND SUPPORT***

If you are interested in learning more or participating, please email Marta Hauser at mhauser@northwell.edu.

CHECK OUT OUR NEW WEBSITE www.vanguardresearchgroup.com AND FOLLOW US ON SOCIAL MEDIA

LinkedIn https://www.linkedin.com/company/vanguardresearchgroup twitter https://twitter.com/VRGResearch facebook https://www.facebook.com/VRGResearch/

VANGUARD RESEARCH GROUP
WEBINAR SERIES 2022
ALL WEBINARS ARE HELD 12-1PM EST

MAY 25th

HOW CMHCS CAN PARTICIPATE IN RESEARCH AND WHY IT IS IMPORTANT FOR CLINICAL PRACTICE (PRESENTER: DR. MARTA HAUSER)

An introduction to different aspects and benefits of conducting research at an agency like yours. What clinical and policy implications have resulted from previous research at CMHCs, how research can be implemented within your agency, and how can we support you in becoming part of the research community.

https://us02web.zoom.us/meeting/register/tZ0rc-CqqTwtH9ZsTBRHSQzNq7aR3ZMxWO2R

JUN 29th

RESEARCH 101 (SESSION 1) – PRACTICAL INTRODUCTION TO RESEARCH IN THE CLINIC (PRESENTER: DR. MARTA HAUSER)

Familiarizing your clinic with a variety of concepts and aspects of research: Institutional Review Boards, Good Clinical Practice, Subject Protection, Safety Reporting and more

https://us02web.zoom.us/meeting/register/tZEvfuCtqT0sH9Ttpor0ArCoyecyu8T3_rNa

JUL 27th

RESEARCH 101 (SESSION 2) – STUDY PROTOCOL AND INFORMED CONSENT (PRESENTER DR. MARTA HAUSER)

Details on the two cornerstones of any study: The study protocol and informed consent

https://us02web.zoom.us/meeting/register/tZMoc--vpj8pHtB0U3VOFRLG1luIlR4291FX

AUG 31st

INTRODUCTION TO THE CONCEPT OF CLINICAL HIGH-RISK OF PSYCHOSIS (PRESENTER DR. MARTA HAUSER)

Signs and symptoms, assessment scales and current practice

https://us02web.zoom.us/meeting/register/tZUlf-qurjopH9QHTWVpXogvtFbHEcXFDw21

SEP 28th

PROTOCOL DEVIATIONS AND CAPAS (CORRECTIVE AND PREVENTATIVE ACTION PLAN) (PRESENTER CRISTINA GONZALEZ)

What counts as a protocol deviation and what to do when it happens

https://us02web.zoom.us/meeting/register/tZcrfuCsrTwtHtEEy0Yk_owGOHla8-k5nlwo

OCT 26th

AN OVERVIEW OF FIRST-EPISODE PSYCHOSIS PROGRAMS – THE EPINET STUDY (PRESENTER DR. DELBERT ROBINSON)

The treatment of first-episode psychosis has come a long way. Maximizing symptomatic and functional recovery remains one of the main goals. Learn more about the approach of the EPINET study.

https://us02web.zoom.us/meeting/register/tZ0vceuppzsvH90tW9s5YwTOk1jUSkjXRxsl

NOV 30th

EXPLORING NEW TECHNOLOGIES, MEDICATIONS AND THERAPIES – ILLUSTRATING DIFFERENT OPPORTUNITIES FOR PARTICIPATING IN CLINICAL STUDIES AND FINDING THE RIGHT TRIAL FOR YOU (PRESENTER PATRICIA MARCY)

Highlighting aspects and examples of studies with different focus and funding sources to determine what best fits your agency

https://us02web.zoom.us/meeting/register/tZMkdeGhrTgvGN2HupncZLz70TM0C1kitscl

DEC 28th

REFLECTION: HOW HAS RESEARCH BEEN WORKING FOR YOU? THE GOOD, THE BAD AND THE THINGS VRG CAN HELP WITH (PRESENTER PATRICIA MARCY)

Whether you have been engaged in research for years or just dipped your toe in – let us know what works well and where change might be needed.

https://us02web.zoom.us/meeting/register/tZwrdeyuqTIsG9C1OO86MgZkzNqeNK0VBP20

No pre-registration required. If you have any questions about participating, please email Marta Hauser at mhauser@northwell.edu

Psychological Medicine

cambridge.org/psm

Relapse prevention through health technology program reduces hospitalization in schizophrenia

Philipp Homan[1,2,3,4,5], Nina R. Schooler[6], Mary F. Brunette[7], Armando Rotondi[8,9], Dror Ben-Zeev[10], Jennifer D. Gottlieb[11], Kim T. Mueser[12], Eric D. Achtyes[13,14], Susan Gingerich[15], Patricia Marcy[16], Piper Meyer-Kalos[17], Marta Hauser[16], Majnu John[1,2,18], Delbert G. Robinson[1,2,3,*] and John M. Kane[1,2,3,*]

[1]Center for Psychiatric Neuroscience, Feinstein Institutes for Medical Research, Manhasset, NY, USA; [2]Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA; [3]Department of Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA; [4]Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital of the University of Zurich, Zurich, Switzerland; [5]Neuroscience Center Zurich, University and ETH, Zurich, Switzerland; [6]Department of Psychiatry, SUNY Downstate Medical School, Brooklyn, NY, USA; [7]Department of Psychiatry, Dartmouth-Hitchcock, Geisel School of Medicine at Dartmouth, Hanover, NH, USA; [8]Department of Critical Care Medicine, Clinical and Translational Sciences Institute, University of Pittsburgh, Pittsburgh, PA, USA; [9]Mental Illness Research, Education and Clinical Center, U.S. Department of Veterans Affairs Medical Center, Pittsburgh, PA, USA; [10]Department of Psychiatry and Behavioral Sciences, Behavioral Research in Technology and Engineering (BRiTE) Center, University of Washington School of Medicine, Seattle, WA, USA; [11]Cambridge Health Alliance, Division of Population Behavioral Health Innovation and Harvard Medical School Department of Psychiatry, Cambridge, MA, USA; [12]Center for Psychiatric Rehabilitation, Boston University, Boston, MA, USA; [13]Cherry Health and Pine Rest Christian Mental Health Services, Grand Rapids, MI, USA; [14]Division of Psychiatry and Behavioral Medicine, Michigan State University College of Human Medicine, Grand Rapids, MI, USA; [15]Independent Consultant and Trainer in Narberth, Narberth, Pennsylvania, USA; [16]Vanguard Research Group, Glen Oaks, NY, USA; [17]University of Minnesota Medical School, Department of Psychiatry & Behavioral Sciences, Minneapolis, MN, USA and [18]Department of Mathematics, Hofstra University, Hempstead, NY, USA

Original Article

*Equal contribution.

Cite this article: Homan P *et al* (2022). Relapse prevention through health technology program reduces hospitalization in schizophrenia. *Psychological Medicine* 1–7. https://doi.org/10.1017/S0033291722000794

Received: 25 March 2021
Revised: 24 December 2021
Accepted: 2 March 2022

Key words:
Schizophrenia; inpatient hospitalization days; relapse prevention; technology provided care; smartphones; web-provided treatments; decision support systems

Author for correspondence:
Delbert G. Robinson,
E-mail: drobinso@northwell.edu

Abstract

Background. Psychiatric hospitalization is a major driver of cost in the treatment of schizophrenia. Here, we asked whether a technology-enhanced approach to relapse prevention could reduce days spent in a hospital after discharge.

Methods. The Improving Care and Reducing Cost (ICRC) study was a quasi-experimental clinical trial in outpatients with schizophrenia conducted between 26 February 2013 and 17 April 2015 at 10 different sites in the USA in an outpatient setting. Patients were between 18 and 60 years old with a diagnosis of schizophrenia, schizoaffective disorder, or psychotic disorder not otherwise specified. Patients received usual care or a technology-enhanced relapse prevention program during a 6-month period after discharge. The health technology program included in-person, individualized relapse prevention planning with treatments delivered via smartphones and computers, as well as a web-based prescriber decision support program. The main outcome measure was days spent in a psychiatric hospital during 6 months after discharge.

Results. The study included 462 patients, of which 438 had complete baseline data and were thus used for propensity matching and analysis. Control participants ($N = 89$; 37 females) were enrolled first and received usual care for relapse prevention followed by 349 participants (128 females) who received technology-enhanced relapse prevention. During 6-month follow-up, 43% of control and 24% of intervention participants were hospitalized ($\chi 2 = 11.76$, $p<0.001$). Days of hospitalization were reduced by 5 days (mean days: $b = -4.58$, 95% CI −9.03 to −0.13, $p = 0.044$) in the intervention condition compared to control.

Conclusions. These results suggest that technology-enhanced relapse prevention is an effective and feasible way to reduce rehospitalization days among patients with schizophrenia.

Introduction

Technology-assisted treatment, incorporating websites, smartphone applications, and self-paced self-management strategies, offers the promise of increasing access to and reach of potentially effective interventions in psychiatry. Different types of technology platforms may be appropriate for different purposes and users, and multiple interventions may be appropriate for individuals with complex, chronic conditions such as schizophrenia (Nasi, Cucciniello, &

Guerrazzi, 2015; O'Shea, McGavigan, Clark, Chew, & Ganesan, 2017). Here, we report outcomes for the Center for Medicaid Services-funded Improving Care and Reducing Cost (ICRC) study (Clinical Trials #NCT02364544) that used multiple technologies to prevent psychiatric hospitalization for patients with schizophrenia who had recently been discharged following an inpatient admission.

Schizophrenia is an important disease target for chronic condition management. Psychiatric hospitalization is a major driver of cost (Ascher-Svanum et al., 2010), relapses and persistent positive symptoms impede recovery and therapeutic alliance (Cavelti, Homan, & Vauth, 2016; Cavelti et al., 2018; Winkelbeiner et al., 2018), and decrease patient quality of life (Almond, Knapp, Francois, Toumi, & Brugha, 2004). For individuals with schizophrenia, poor treatment adherence, discontinuation, and service rejection are common (Higashi et al., 2013). These characteristics drive the need for a novel multicomponent approach to patient engagement and relapse prevention (Baumel et al., 2016; Brunette et al., 2016): The 6-month 'health technology program' (HTP) included in-person, individualized relapse prevention planning that involved treatments delivered via smartphones and computers, as well as a web-based prescriber decision support program (Fig. 1*a*).

A 'mental health technology coach' (MHTC) worked in a team to provide the HTP. Based on the stress-vulnerability coping model (Mueser, Corrigan, & Hilton, 2002) and supported by smartphone- and computer-based treatments, the MHTC developed a personalized relapse prevention plan with the patient (Brunette et al., 2016). Since previous studies suggest that relapse prevention planning is an effective approach for patients with schizophrenia (Mueser et al., 2002), we hypothesized that HTP compared to standard relapse prevention would decrease rehospitalization days during the 6-month intervention period after a recent hospitalization compared to usual care. Note that data from the CATIE study (Lieberman et al., 2005) have documented that the 6 months following an admission for a psychotic episode is a period of high risk for rehospitalization and thus was the chosen period we examined in the study.

Materials and methods

Study participants and design

Inclusion criteria were age between 18 and 60 years; diagnosis of schizophrenia, schizoaffective disorder, or psychotic disorder not otherwise specified; discharge from psychiatric hospitalization within the past 60 days; ability to participate in research assessments in English; and ability to provide informed consent. Patients with a serious general medical condition were excluded. Note that having WIFI and a personal computer were not inclusion criteria. To enhance participation equity, we eliminated the potential for participation being restricted by participant financial constraints by providing a smartphone and a personal computer to participants while they were in the study.

Medication data were collected at study entry, 3 months, and 6 months. Supplementary Table S1 presents the percentage of participants receiving antipsychotic treatment divided into critical categories at each medication data collection time period. At study entry, the percentage of control and intervention participants receiving any antipsychotic, clozapine, and long-acting injectable antipsychotics (LAIs) was very similar; there was no evidence for differences between any proportion. The use of LAIs and clozapine was more common than in many outpatient settings and this probably reflects that participants had had at least two inpatient admissions for psychotic episodes prior to study entry.

The study was conducted at 10 sites in eight US states. Following a quasi-experimental design, up to 10 patients at each site were enrolled and assessed to form a control group starting on 26 February 2013. After completion of the control group enrollment, patients were enrolled in the experimental condition until 17 April 2015. Note that each site recruited control subjects and subsequently intervention subjects. Thus the control and intervention participants came from the same facilities. All patients provided written informed consent. The Feinstein Institutional Review Board (IRB) approved and monitored the overall study; if required by a given site, a local IRB also approved the study.

Intervention

Details of the intervention have been previously published (Baumel et al., 2016; Brunette et al., 2016). Briefly, the 6-month HTP provides in-person, individualized relapse prevention planning that directs use of technology-based treatments delivered on smartphones and computers and provides a web-based prescriber decision support program.

Prescriber Decision Support System

Pharmacotherapy guidelines were implemented in HTP by using a computerized clinical decision support system with a measurement-based care approach, modeled on a system developed for the RAISE-ETP study (Recovery After an Initial Schizophrenia Episode Early Treatment Program), which was funded by the National Institute of Mental Health. All HTP prescribers and clients accessed the program from a secure website. Prior to each prescriber visit, the client entered information into the system by answering a series of simple questions about symptoms, side effects, and treatment preferences. The prescriber then reviewed these data, which guide the in-person evaluation session. The system includes recommendations about evidence-based medication strategies that inform joint client–prescriber decision making, as well as suggestions for other HTP interventions (e.g. 'Coping With Voices' for clients with auditory hallucinations).

Relapse prevention plan

The case manager and client collaboratively develop a personal plan by exploring reasons for preventing relapses; reviewing the last relapse; identifying early warning signs, triggers, and preventive strategies; making a plan to monitor and respond to early warning signs; identifying specific coping strategies; and seeking input from natural supports (e.g. family). A brief manual and worksheets supported the process of creating, learning, and sharing the plan with other service providers and supportive persons, as well as using the plan to guide deployment of technology-based treatments.

Smartphone intervention for schizophrenia

FOCUS is a smartphone system that has five modules which are designed to enhance coping with symptoms, mood, or sleep problems; improve social situations; and encourage medication use. Participants can select FOCUS content on the basis of persistent symptoms or sources of stress that increase risk of relapse. FOCUS

https://doi.org/10.1017/S0033291722000794 Published online by Cambridge University Press



Fig. 1. Health technology program reduces rehospitalization. (*a*) Study design. After discharge from the psychiatric hospital across 10 US sites, patients were non-randomly assigned for 6 months to either the standard relapse prevention group (SRG) or the health technology program (HTP). A mental health technology coach (MHTC) guided the patient through the program, providing coaching, monitoring, and close coordination with a psychiatric prescriber. Note that HTP included (1) contacts with the MHTC to develop and maintain a relapse prevention plan; (2) an interactive smartphone illness self-management system providing coping strategy training and brief interventions to improve medication adherence, mood regulation, sleep, social functioning, and coping with auditory hallucinations; (3) a daily support website for patients and relatives focusing on psychoeducation; (4) a web-based, self-administered, self-paced cognitive behavioral therapy for psychosis (CBTp) sessions for coping with voices and coping with paranoia; and (5) evidence-based pharmacological treatment. (*b*) Significant reduction in days spent in the hospital after discharge. Compared to the SRG, the 6-month HTP significantly reduced the mean stay in psychiatric hospitals after discharge. Mean cumulative difference in days during 6 months with 95% confidence intervals is shown.

uses system-generated audio prompts and on demand resources (visual aids, photos, and cartoons) and written text to teach evidence-based coping strategies through interactive assessments, exercises, and suggestions that clients can access as they encounter challenges in their daily lives.

The Daily Support Website

The Daily Support Website (DSW) uses both web- and phone-based resources to support illness management and recovery for persons with schizophrenia and their supporters. The program provides education about schizophrenia, teaches problem-solving skills, and facilitates social support for clients and their relatives and other supporters to reduce family stress and improve coping in order to prevent relapses. The DSW includes web-based group forums, a library of educational resources, an 'ask the expert' service, a 'frequently asked questions' library, and a news feed. The forums (one each for clients and supporters and one for both) are facilitated by therapists who promote and emphasize discussions on solving problems, alleviating stress, and increasing social support.

Computerized Cognitive Behavioral Therapy for Psychosis (CBTp)

Two web-based CBTp skills programs, 'Coping With Voices' and 'Coping With Paranoia', incorporate traditional elements of CBTp, including goal setting, psychoeducation, normalization of symptoms, coping strategy enhancement, cognitive restructuring, and home practice. The programs help clients develop strategies to cope with voices and paranoia to prevent symptoms from escalating to a relapse. The programs are interactive and self-paced. They include animated tutorials, exercises, and games; personal symptom and goals tracking; and independent skills practice worksheets. Participants progress through modules, cumulatively building skills.

Whether sessions were prompted by an investigator or were initiated by the participants depended upon the intervention. Specifically, the DSW that provided support and education to patients and families and the CBT program for voices and paranoia were participant initiated. The FOCUS smartphone app gave prompts to participants but also had participant-initiated features. The computer support system for medication decision making was incorporated into the routine patient–prescriber visit.

The intervention was flexible regarding which components participants employed. Participants were provided an introduction to all the intervention components and they could choose their level of participation. Participants usually had monthly prescriber visits but could have more frequent visits based upon clinical need. All participants had an individualized relapse prevention plan. This usually took four sessions to develop and one later to review at the end of study participation. Of the remaining interventions, the smartphone app is the simplest to use and is usually the technology tool that is first used by participants. Detailed use patterns for the smartphone app have been previously published (Achtyes et al., 2019; Ben-Zeev et al., 2016).

Primary outcome

The primary outcome measure was days spent in a psychiatric hospital during 6 months after discharge, as assessed by a monthly patient interview.

Statistical analysis

We hypothesized that participants in the HTP compared with the control group would have fewer days of hospitalization. We used a linear mixed model with inverse probability of treatment weighting (IPTW) to estimate the treatment effect. We then used these stabilized weights to weight each participant's outcome, the number of days spent in a psychiatric hospital, which was the primary outcome measure, and used treatment [standard relapse prevention group (SRG) *v.* HTP] and number of visits as predictors. We also included predictors for all the covariates that were used to calculate the propensity scores, including age, gender, race, diagnosis, socioeconomic status, study site, quality of life at baseline, cannabis and alcohol abuse, age at illness onset, age at first hospitalization, number of prior hospitalizations, length of last hospitalization, and days in medical treatment. A custom contrast comparing the difference of cumulative days spent in the hospital over the 6 months period between groups was then calculated.

https://doi.org/10.1017/S0033291722000794 Published online by Cambridge University Press

The estimate of this treatment effect is reported as raw estimate (difference in days) with 95% confidence intervals. We also report balance diagnostics of the IPTW (Austin & Stuart, 2015) which compare the baseline covariates before and after applying inverse propensity weights. We considered successful removal of confounding conditional on the IPTW by differences between covariates that were smaller than Cohen's $d = 0.1$ for continuous covariates and smaller than Cramer's $V = 0.1$ for categorical covariates (Austin & Stuart, 2015). Finally, we also tested for an effect of HTP on quality of life at month 6, using an IPTW weighted linear regression with the same covariates as in our primary analysis (see above).

Results

From the participants assigned to the SRG group, a total of 89 participants had complete data for propensity matching and were thus used in the final study. From the participants assigned to the HTP program, 349 participants had complete data for propensity matching and were used in the final study. Weighting the baseline covariates with inverse propensity scores resulted in a more balanced study sample (Austin & Stuart, 2015), with all covariates showing effect size differences smaller than Cohen's $d = 0.1$ and Cramer's $V = 0.1$, respectively (online Supplementary Fig. S1). In addition, both groups showed high rates of study completion, with a higher rate in the HTP group that did not reach statistical significance [χ^2 (1) = 2.9, $p = 0.088$; Table 1].

Over 6 months and compared to the SRG group, the HTP reduced the days of hospitalization by 5 days (mean days: $b = -4.58$, 95% CI −9.03 to −0.13, $p = 0.044$; Fig. 1*b*). Mean estimated days of hospitalization during 6 months for the SRG group were 16.21 and 11.64 for the HTP group.

To confirm that this effect was robust to the skewed distribution we repeated our analysis with a log-transformation of the days in hospital (to attenuate the skew) and confirmed that there were fewer hospitalization days during the HTP program compared to control treatment ($b = 0.38$, S.E. = 0.16, $t = 2.42$, $p < 0.05$).

In terms of ratios of participants who were rehospitalized with respect to the two groups, there were 38/89 (43%) patients rehospitalized from the control group and 83/349 (24%) patients from the HTP group. Note that this difference in rehospitalized patients was significant ($\chi^2 = 11.76$, $p < 0.001$). Thus, the proportion of rehospitalized patients was significantly higher in the control group than in the HTP group, confirming our main finding.

We also examined the influence of age by looking at the effect of age in our model. Interestingly, while we did not find that this effect was significant, the sign of the effect was negative, suggesting that if anything older patients spent fewer days at the hospital ($b = -0.03$, S.E. = 0.02, $t = -1.75$, $p > 0.05$).

Finally, using quality of life at month 6 as outcome, we found no significant effect of HTP [$\beta = 0.02$, t (345) = 0.43, $p = 0.668$].

Discussion

Recently hospitalized patients with schizophrenia who received an integrated technology-informed relapse prevention program (HTP) experienced fewer days in the hospital compared to those who received usual care in the 6 months following their discharge. Given the high patient burden and costs of even a single day spent in a psychiatric hospital, estimated at $1358 per day based on inflation-adjusted results from a recent study (Rosenheck et al., 2016), our findings imply total savings in psychiatric inpatient expenditures of $6216 during the first 6 months after discharge on average, suggesting potentially important health-economic implications (Ben-Zeev, Razzano, Pashka, & Levin, 2021), even after additional intervention costs are taken into consideration. Technology-enhanced relapse prevention that is tailored to the individual patient may improve recovery and the ability of individuals to remain in the community, and reduce the costs for the management of schizophrenia significantly, offsetting technology access costs. In addition, the high acceptance and satisfaction reported previously (Baumel et al., 2016) suggest that these patients are willing and able to engage in a novel and technology-enhanced approach to relapse prevention. This approach offers potential to overcome the sometimes low satisfaction with services reported by patients.

The question of whether technology-assisted treatment is more readily and effectively used by different population subgroups is one interesting and important question. For example, the cultural image of individuals who use technology extensively is that of young men. One could also hypothesize that educated compared to less educated participants would be more likely to use technology-assisted treatment. The FOCUS smartphone app recorded detailed metrics of use to test these associations. An analysis of high utilizers of FOCUS previously published (Achtyes et al., 2019) identified that high utilizers were indeed more likely to be more educated but contrary to cultural expectations were more likely to be women than men and older compared with younger individuals. However, the main result of the current study was not influenced by age.

Schizophrenia is usually chronic and characterized by relapse. Crucially, relapse may reduce future treatment response and contribute to treatment resistance (Emsley, Nuamah, Hough, & Gopal, 2012; Takeuchi et al., 2018; Wiersma, Nienhuis, Slooff, & Giel, 1998), highlighting the need for interventions after hospitalization that improve outcomes and reduce health care cost. Although technology-based intervention studies for patients with schizophrenia have shown promise (Alvarez-Jimenez et al., 2014; Rotondi et al., 2010), the current study suggests that engagement with technological interventions requires the support of trained personnel (Mohr, Cuijpers, & Lehman, 2011).

Four features of HTP were likely to drive the beneficial impact of the intervention (Baumel et al., 2016). First, HTP included relapse prevention planning, cognitive-behavioral symptom management strategies, and family psychoeducation strategies, all of which are evidence-based and address common symptoms and distress. Second, in-person assistance through the MHTC may have enhanced the use of the digital tools. Third, patient's ratings suggest that the design of the tools was helpful (e.g. easy to use for those with cognitive deficits common in schizophrenia). Finally, the HTP approach to relapse prevention was flexible, with most contacts between the MHTC and patient occurring via technologies such as mobile phones, text, and e-mail.

While the coordinated specialty care (CSC) model (Jones et al., 2020) has transformed the standard of in-person care for first-episode schizophrenia (emphasizing a team-based, multi-element approach to address the complex and varied needs of this population), significant barriers remain, a crucial element of which is cost (Ben-Zeev, Buck, Kopelovich, & Meller, 2019). As shown in this report, technology does not have to exclude human interactions, but instead can be additive to human-delivered, evidence-based treatment, and most importantly can reduce costs. Consistent with CSC, HTP technologies are emphasizing a multi-

Table 1. Sample characteristics of the ICRC study

Characteristic	SRG, *N*	SRG, %	Mean	S.D.	HTP, *N*	HTP, %	Mean	S.D.
Age	89	100	35.44	10.04	349	100	34.53	10.89
Females	37	41.57			128	36.68		
Males	52	58.43			221	63.32		
Completers	75	84.27			318	91.12		
Cumulative days in hospital	89	100	7.7	17.2	349	100	4.7	14.63
White	50	56.18			169	48.42		
Black	21	23.6			90	25.79		
American Indian	2	2.25			4	1.15		
Asian	6	6.74			19	5.44		
Hispanic	6	6.74			40	11.46		
Pacific Islander	0	0			2	0.57		
Two or more races	4	4.49			25	7.16		
Schizophrenia	44	49.44			172	49.28		
Schizoaffective	45	50.56			162	46.42		
Psychosis not otherwise specified	0	0			21	6.02		
Age at onset	89	100	17.09	8.03	349	100	18.77	8.08
Age at first hospitalization	89	100	21.97	7.96	349	100	22.62	7.49
Postgraduate	2	2.25			7	2.01		
Postgraduate training	5	5.62			3	0.86		
College	5	5.62			24	6.88		
Postsecondary	33	37.08			148	42.41		
High school	19	21.35			88	25.21		
High school no diploma	22	24.72			67	19.2		
Eighth grade	2	2.25			6	1.72		
Attended grade school	0	0			6	1.72		
No schooling	1	1.12			0	0		

ICRC, improving care and reducing cost; SRG, standard relapse prevention group; HTP, heath technology program.

component approach: they connect the client with others to create a team of community case managers, employment specialists, therapists, and people with lived experience that can help them succeed. Thus, HTP is a prime example of emerging technologies that may serve as the key scaffold to implementing effective practices in a scalable, personalized, and sustainable manner.

Importantly, evidence suggests that individuals with schizophrenia do use electronic devices, and they use it in a manner that is comparable to those without schizophrenia (Ben-Zeev et al., 2019). In addition, there is strong evidence suggesting that younger generations – so-called digital natives (Prensky, 2001) who grew up with the Internet and with smartphones – will be capable and willing to use familiar technologies for mental health (Abdel-Baki, Lal, D-Charron, Stip, & Kara, 2015; Lal, Dell'Elce, & Malla, 2015).

The current study has some limitations that merit comment. One cannot rule out that treatment globally may have become more sophisticated over a 2-year period. However, there are several factors that suggest that important changes in treatment during a 2-year period are unlikely. First, ICRC was done at 10 sites widely dispersed across the United States. Thus, treatment changes would have had to occur not locally but across the United States to be important factors in the study outcomes. Nation-wide changes are possible but occur very slowly with the diversified health care system in the United States. Second, no major new treatment paradigms for patients with multi-episode psychosis were released during the study period. We and all clinicians wish that major advances comparable to earlier advances such as the development of clozapine had occurred during the study period but unfortunately impactful treatment advances rarely occur.

Another limitation is that we did not use patients' own phones or computers. However, as troubleshooting of technical issues becomes more complex with multiple types of computers and smartphones, this was greatly improved by providing the same phones and computers to all participants. This greatly facilitated fixing technical issues as one has to solve issues with only one phone and one computer instead of the myriad of different models if using participant provided equipment. Further, regarding future clinical implementation of a HTP, developers can

https://doi.org/10.1017/S0033291722000794 Published online by Cambridge University Press

proactively tailor solutions to particular issues (e.g. the cellphone service provider upgrading cell phone operating systems remotely) knowing that solutions are needed for only a particular smartphone and computer.

Clearly, the non-randomized study design is an additional limitation of this study. However, data on high satisfaction and low drop out which we have presented in a previous publication (Baumel et al., 2016) showed that 93% of enrolled patients completed the 6-month program, and 89% completed the program review; and that 72% were very satisfied and 24% were somewhat satisfied with the intervention. Thus, the high satisfaction and usability reported previously (Baumel et al., 2016) as well as low dropout suggests that HTP is a feasible and potentially effective way to increase engagement with treatment and reduce hospitalization days in schizophrenia. Consequently, technology-based treatments (Ben-Zeev et al., 2014) that involve the support of trained personnel (Ben-Zeev, Drake, & Marsch, 2015; Mohr et al., 2011) may be an efficient alternative to conventional relapse prevention approaches that are hampered by the limited availability of highly trained staff. More rigorously controlled research is needed to evaluate the effects of the HTP program, and other technology-informed programs for reducing relapses and rehospitalizations for persons with schizophrenia at risk for rehospitalization. Obviously, there are relevant concerns about the use of technology in mental health care, including privacy breaches and the fear of replacing human-delivered care; such concerns must be addressed. However, if addressed there is also great potential for technology to improve mental health care, whether employed independently or with the assistance of a care team. In addition, although a cost-effectiveness analysis would have been valuable that was not built into this project and we did not track the exact number of visits; we were focused on feasibility and clinical impact. Finally, while there were multiple tech tools available to the participants and to the treatment providers, we did not collect a single measure that represents overall use of all the tools.

Much of current medical practice involves treatment of chronic conditions that impair patients in multiple domains and thereby require complex interventions. Schizophrenia, a disease often associated with motivational, cognitive, and executive dysfunctions, is an example of a condition with such treatment complexities. Given the success of the HTP model for participants with schizophrenia, treatment models with multiple technologies that allow for individualization of services, which are coordinated and facilitated by a health coach, may be feasible in the management of other chronic diseases requiring complex management strategies.

Supplementary material. The supplementary material for this article can be found at https://doi.org/10.1017/S0033291722000794

Data. The data and code of this study are shared online to ensure reproducibility, doi: 10.17605/OSF.IO/YHVCE.

Acknowledgements. Supported by grant 1C1CMS331052-01-00 from the Centers for Medicare and Medicaid Services, Department of Health and Human Services. The contents of this report are solely the responsibility of the authors and do not necessarily represent the official views of the US Department of Health and Human Services or any of its agencies.

Conflict of interest. Drs Hauser and Rotondi have been consultants to Otsuka. Dr Brunette holds a research contract with Alkermes. Dr Ben-Zeev has been a consultant for eQuility and has had an intervention content licensing agreement with Pear Therapeutics. Dr Achtyes has served on advisory boards for Alkermes, Janssen, Karuna, Lundbeck/Otsuka, Roche, Sunovion, and Teva and reports previous stock holdings in AstraZeneca, Johnson & Johnson, Moderna, and Pfizer. Dr Achtyes has received research support from Alkermes, Astellas, Biogen, Boehringer-Ingelheim, InnateVR, Janssen, National Network of Depression Centers, Neurocrine Biosciences, Novartis, Otsuka, Pear Therapeutics, and Takeda. Dr Schooler has served on advisory boards or as a consultant for Abbott, Alkermes, Amgen, Eli Lilly, Forum (formerly EnVivo), Janssen Psychiatry, Roche, and Sunovion. She has received grant or research support from Genentech, Neurocrine, and Otsuka. Dr Robinson has been a consultant to Asubio, Costello, Innovative Science Solutions, and Shire, and he has received grants from Bristol-Myers Squibb, Janssen, and Otsuka. Marcy is a shareholder in Pfizer. Dr Kane has been a consultant for Alkermes, Eli Lilly, EnVivo Pharmaceuticals (Forum), Forest, Genentech, Intracellular Therapeutics, Janssen Pharmaceutica, Johnson and Johnson, Lundbeck, Neurocrine, Newron, Otsuka, Pierre Fabre, Proteus, Reviva, Roche, Saladex, Sunovion, and Teva. He has received lecture honoraria from Genentech, Janssen, Lundbeck, and Otsuka. He is a shareholder in LB Pharmaceuticals, and Vanguard Research Group. All other authors have no conflict of interest.

References

Abdel-Baki, A., Lal, S., D-Charron, O., Stip, E., & Kara, N. (2015, May). Understanding access and use of technology among youth with first-episode psychosis to inform the development of technology-enabled therapeutic interventions. *Early Intervention in Psychiatry*, *11*(1), 72–76. http://doi.org/10.1111/eip.12250.

Achtyes, E. D., Ben-Zeev, D., Luo, Z., Mayle, H., Burke, B., Rotondi, A. J., … Kane, J. M. (2019). Off-hours use of a smartphone intervention to extend support for individuals with schizophrenia spectrum disorders recently discharged from a psychiatric hospital. *Schizophrenia Research*, *206*, 200–208. http://doi.org/10.1016/j.schres.2018.11.026.

Almond, S., Knapp, M., Francois, C., Toumi, M., & Brugha, T. (2004). Relapse in schizophrenia: Costs, clinical outcomes and quality of life. *The British Journal of Psychiatry*, *184*(4), 346–351.

Alvarez-Jimenez, M., Alcazar-Corcoles, M., Gonzlez-Blanch, C., Bendall, S., McGorry, P., & Gleeson, J. (2014). Online, social media and mobile technologies for psychosis treatment: A systematic review on novel user-led interventions. *Schizophrenia Research*, *156*(1), 96–106. http://doi.org/10.1016/j.schres.2014.03.021.

Ascher-Svanum, H., Zhu, B., Faries, D. E., Salkever, D., Slade, E. P., Peng, X., & Conley, R. R. (2010). The cost of relapse and the predictors of relapse in the treatment of schizophrenia. *BMC Psychiatry*, *10*(1). http://doi.org/10.1186/1471-244x-10-2.

Austin, P. C., & Stuart, E. A. (2015). Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. *Statistics in Medicine*, *34*(28), 3661–3679. https://doi.org/10.1002/sim.6607.

Baumel, A., Correll, C. U., Hauser, M., Brunette, M., Rotondi, A., Ben-Zeev, D., … Kane, J. M. (2016). Health technology intervention after hospitalization for schizophrenia: Service utilization and user satisfaction. *Psychiatric Services*, *67*(9), 1035–1038. https://doi.org/10.1176/appi.ps.201500317.

Ben-Zeev, D., Brenner, C. J., Begale, M., Duffecy, J., Mohr, D. C., & Mueser, K. T. (2014). Feasibility, acceptability, and preliminary efficacy of a smartphone intervention for schizophrenia. *Schizophrenia Bulletin*, *40*(6), 1244–1253. https://doi.org/10.1093/schbul/sbu033.

Ben-Zeev, D., Buck, B., Kopelovich, S., & Meller, S. (2019). A technology-assisted life of recovery from psychosis. *NPJ Schizophrenia*, *5*(1). https://doi.org/10.1038/s41537-019-0083-y.

Ben-Zeev, D., Drake, R., & Marsch, L. (2015). Clinical technology specialists. *BMJ*, *350*(feb19 15), h945–h945. https://doi.org/10.1136/bmj.h945.

Ben-Zeev, D., Razzano, L. A., Pashka, N. J., & Levin, C. E. (2021). Cost of mhealth versus clinic-based care for serious mental illness: Same effects, half the price tag. *Psychiatric Services*. https://doi.org/10.1176/appi.ps.202000349.

Ben-Zeev, D., Scherer, E. A., Gottlieb, J. D., Rotondi, A. J., Brunette, M. F., Achtyes, E. D., … Kane, J. M. (2016). Mhealth for schizophrenia: Patient engagement with a mobile phone intervention following hospital discharge. *JMIR Mental Health*, *3*(3), e34. http://dx.doi.org/10.2196/mental.6348.

Brunette, M. F., Rotondi, A. J., Ben-Zeev, D., Gottlieb, J. D., Mueser, K. T., Robinson, D. G., … Kane, J. M. (2016). Coordinated technology-delivered treatment to prevent rehospitalization in schizophrenia: A novel model of care. *Psychiatric Services*, *67*(4), 444–447. https://doi.org/10.1176/appi.ps.201500257.

Cavelti, M., Homan, P., & Vauth, R. (2016). The impact of thought disorder on therapeutic alliance and personal recovery in schizophrenia and schizoaffective disorder: An exploratory study. *Psychiatry Research*, *239*, 92–98. https://doi.org/10.1016/j.psychres.2016.02.070.

Cavelti, M., Winkelbeiner, S., Federspiel, A., Walther, S., Stegmayer, K., Giezendanner, S., … Homan, P. (2018). Formal thought disorder is related to aberrations in language-related white matter tracts in patients with schizophrenia. *Psychiatry Research: Neuroimaging*, *279*(279), 40–50. https://doi.org/10.1016/j.pscychresns.2018.05.011.

Emsley, R., Nuamah, I., Hough, D., & Gopal, S. (2012). Treatment response after relapse in a placebo- controlled maintenance trial in schizophrenia. *Schizophrenia Research*, *138*(1), 29–34. https://doi.org/10.1016/j.schres.2012.02.030.

Higashi, K., Medic, G., Littlewood, K. J., Diez, T., Granström, O., & De Hert, M. (2013). Medication adherence in schizophrenia: Factors influencing adherence and consequences of nonadherence, a systematic literature review. *Therapeutic Advances in Psychopharmacology*, *3*(4), 200–218. https://doi.org/10.1177/2045125312474019.

Jones, N., Gius, B., Daley, T., George, P., Rosenblatt, A., & Shern, D. (2020). Coordinated specialty care discharge, transition, and step-down policies, practices, and concerns: Staff and client perspectives. *Psychiatric Services*, *71*(5), 487–497. https://doi.org/10.1176/appi.ps.201900514.

Lal, S., Dell'Elce, J., & Malla, A. K. (2015). Technology access and use among young adults with a first episode of psychosis. *Psychiatric Services*, *66*(7), 764–765. https://doi.org/10.1176/appi.ps.201400580.

Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., … Hsiao, J. K. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *New England Journal of Medicine*, *353*(12), 1209–1223. https://doi.org/10.1056/nejmoa051688.

Mohr, D. C., Cuijpers, P., & Lehman, K. (2011). Supportive accountability: A model for providing human support to enhance adherence to ehealth interventions. *Journal of Medical Internet Research*, *13*(1), e30. http://doi.org/10.2196/jmir.1602.

Mueser, K., Corrigan, P., & Hilton, D. (2002). Illness management and recovery: A review of the research. *Psychiatric Services*, *53*, 1272–1284. http://doi.org/10.1176/appi.ps.53.10.1272.

Nasi, G., Cucciniello, M., & Guerrazzi, C. (2015). The role of mobile technologies in health care processes: The case of cancer supportive care. *Journal of Medical Internet Research*, *17*(2), e26. https://doi.org/10.2196/jmir.3757.

O'Shea, C. J., McGavigan, A. D., Clark, R. A., Chew, D. P. B., & Ganesan, A. (2017). Mobile health: An emerging technology with implications for global internal medicine. *Internal Medicine Journal*, *47*(6), 616–619. https://doi.org/10.1111/imj.13440.

Prensky, M. (2001). Digital natives, digital immigrants part 1. *On the Horizon*, *9*(5), 1–6. https://doi.org/10.1108/10748120110424816.

Rosenheck, R., Leslie, D., Sint, K., Lin, H., Robinson, D. G., Schooler, N. R., … Kane, J. M. (2016). Cost-effectiveness of comprehensive, integrated care for first episode psychosis in the NIMH RAISE early treatment program. *Schizophrenia Bulletin*, *42*(4), 896–906. https://doi.org/10.1093/schbul/sbv224.

Rotondi, A. J., Anderson, C. M., Haas, G. L., Eack, S. M., Spring, M. B., Ganguli, R., … Rosenstock, J. (2010). Web-based psychoeducational intervention for persons with schizophrenia and their supporters: One-year outcomes. *Psychiatric Services*, *61*(11), 1099–1105. https://doi.org/10.1176/ps.2010.61.11.1099.

Takeuchi, H., Siu, C., Remington, G., Fervaha, G., Zipursky, R. B., Foussias, G., & Agid, O. (2018). Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. *Neuropsychopharmacology*, *44*(6), 1036–1042. https://doi.org/10.1038/s41386-018-0278-3.

Wiersma, D., Nienhuis, F. J., Slooff, C. J., & Giel, R. (1998). Natural course of schizophrenic disorders: A 15-year followup of a Dutch incidence cohort. *Schizophrenia Bulletin*, *24*(1), 75–85. https://doi.org/10.1093/oxfordjournals.schbul.a033315.

Winkelbeiner, S., Cavelti, M., Federspiel, A., Kunzelmann, K., Dierks, T., Strik, W., … Homan, P. (2018). Decreased blood flow in the right insula and middle temporal gyrus predicts negative formal thought disorder in schizophrenia. *Schizophrenia Research*, *201*, 432–434. https://doi.org/10.1016/j.schres.2018.06.009.